Inhibitors of micro-RNAs for use for preventing and/or attenuating skin ageing

Patent metadata

Field	Value
Publication number	US-9568467-B2
Application number	US-201314012128-A
Country	US
Kind code	B2
Filing date	Aug 28, 2013
Priority date	Aug 29, 2012
Publication date	Feb 14, 2017
Grant date	Feb 14, 2017

Abstract

Identification and use of compounds which inhibit the expression or activity of micro-RNAs for preventing and/or attenuating ageing. An in vitro method for screening for candidate compounds for preventing and/or attenuating ageing of the skin including (a) bringing at least one test compound in contact with a sample of fibroblasts, (b) measuring the expression or the activity of at least one microRNA chosen from miR-134 and miR-152 in said fibroblasts, and (c) selecting the compounds for which an inhibition of at least 20%, preferably at least 30%, preferably at least 40% of the expression or an inhibition of at least 20%, preferably at least 30%, preferably at least 40% of the activity of at least one microRNA is measured in the fibroblasts treated in (a) compared with the untreated fibroblasts.

First claim

The invention claimed is:

1. An in vitro method for screening for candidate compounds for attenuating ageing of the skin, comprising the following steps:
(a) bringing at least one test compound in contact with at least one sample of fibroblasts;
(b) measuring the expression or the activity of at least one microRNA chosen from miR-134 and miR-152 in said fibroblasts;
(c) selecting the compounds for which an inhibition of at least 20% of the expression, or an inhibition of at least 20% of the activity, of said at least one microRNA is measured in the fibroblasts treated in step (a) compared with untreated fibroblasts.

2. The method according to claim 1 , wherein step (b) is performed before and after step (a).

3. The method according to claim 1 , wherein the test compounds are chosen from botanical extracts.

4. The method according to claim 1 , wherein the inhibition of expression or activity of the microRNA measured in step (c) is at least 50%.

5. The method according to claim 1 , wherein the inhibition of expression or activity of the microRNA measured in step (c) is at least 40%.

6. The method according to claim 1 , wherein the inhibition of expression or activity of the microRNA measured in step (c) is at least 60%.

7. The method according to claim 1 , wherein the at least one microRNA in step (b) is miR-134.

8. The method according to claim 1 ,
wherein said fibroblasts are pre-senescent fibroblasts that have been obtained after 70 population doublings in classical culture conditions,
wherein the classical culture conditions comprise culturing the fibroblasts in 106 medium added with LSGS growth supplements, and constantly keeping the fibroblasts in a subconfluent state.

9. The method according to claim 1 , wherein said fibroblasts are pre-senescent fibroblasts.

10. The method according to claim 9 , wherein the pre-senescent fibroblasts are obtained after 70 population doublings in classical culture conditions.

11. The method according to claim 10 , wherein the classical culture conditions comprise culturing the fibroblasts in 106 medium added with LSGS growth supplements, and constantly keeping the fibroblasts in a subconfluent state.

12. An in vitro method for screening for candidate compounds for attenuating ageing of the skin, comprising the following steps:
(a′) preparing at least two samples of fibroblasts;
(a) bringing at least one test compound into contact with at least one of said at least two samples of fibroblasts, while leaving at least one of said two samples of fibroblast untreated; then
(b) measuring the expression or the activity of at least one microRNA chosen from miR-134 and miR-152 in said at least two samples of fibroblasts; and
(c) selecting the compounds for which an inhibition of at least 20% of the expression, or an inhibition of at least 20% of the activity, of said at least one microRNA is measured in the at least one sample of fibroblasts brought into contact with the at least one test compound treated in step (a) compared with the sample of untreated fibroblasts.

Assignees

• Chanel Parfums Beaute

Inventors

• Candi Eleonora
• Melino Gerry
• Saintigny Gaelle
• Mahe Christian

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K8/9794

  Liliopsida [monocotyledons] · CPC title

• A61K8/9789

  Magnoliopsida [dicotyledons] · CPC title

• C12Q1/26

  involving oxidoreductase · CPC title

• A61Q19/08

  Anti-ageing preparations · CPC title